Factors that influence outcome in non-invasive and invasive treatment in polycystic liver disease patients

World J Gastroenterol. 2008 May 28;14(20):3195-200. doi: 10.3748/wjg.14.3195.

Abstract

Aim: To evaluate the factors that influence outcome of both non-invasive and invasive treatment of polycystic liver disease.

Methods: Analysis of clinical files of patients with complete follow-up from July 1986 to June 2006.

Results: Forty-one patients (male, 7; female, 34), 47.8 +/- 11.9 years age, and 5.7 +/- 6.7 years follow-up, were studied. Alkaline phosphatase (AP) elevation (15% of patients) was associated with the requirement of invasive treatment (IT, P = 0.005). IT rate was higher in symptomatic than non-symptomatic patients (65.4% vs 14.3%, P = 0.002), and in women taking hormonal replacement therapy (HRT) (P = 0.001). Cysts complications (CC) were more frequent (22%) in the symptomatic patients group (P = 0.023). Patients with body mass index (BMI) > 25 (59%) had a trend to complications after IT (P = 0.075). Abdominal pain was the most common symptom (56%) and indication for IT (78%). Nineteen patients (46%) required a first IT: 12 open fenestration (OF), 4 laparoscopic fenestration (LF) and 3 fenestration with hepatic resection (FHR). Three required a second IT, and one required a third procedure. Complications due to first IT were found in 32% (OF 16.7%, LF 25%, FHR 66.7%), and in the second IT in 66.7% (OF 100%). Follow-up mortality rate was 0.

Conclusion: Presence of symptoms, elevated AP, and CC are associated with IT requirement. HRT is associated with presence of symptoms and IT requirement. Patients with BMI > 25 have a trend be susceptible to IT complications. The proportions of complications are higher in FHR and second IT groups. RS is more frequent after OF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alkaline Phosphatase / blood
  • Body Mass Index
  • Cysts / complications
  • Cysts / etiology
  • Cysts / pathology
  • Cysts / therapy*
  • Digestive System Surgical Procedures / adverse effects
  • Estrogen Replacement Therapy / adverse effects
  • Female
  • Follow-Up Studies
  • Humans
  • Liver Diseases / complications
  • Liver Diseases / etiology
  • Liver Diseases / pathology
  • Liver Diseases / therapy*
  • Male
  • Middle Aged
  • Odds Ratio
  • Recurrence
  • Reoperation
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome

Substances

  • Alkaline Phosphatase